5 Best Mid Cap Stocks To Buy Right Now

The Q3 2014 earnings report for mid cap�online real estate information stock Zillow Inc (NASDAQ: Z), a peer of small cap�Move Inc (NASDAQ: MOVE) which News Corp (NASDAQ: NWSA) is acquiring and small cap�Trulia Inc (NYSE: TRLA) which Zillow is also acquiring, is scheduled for after the market's close on Wednesday (November 5th). Aside from the Zillow Inc earnings report, it should be said that Move Inc reported Q2 2014 earnings on July 29th (revenue rose 7% to $61.3M, average monthly unique users of realtor.com庐's web and mobile sites grew 18% to 31.2M and Non-GAAP Loss Per Share was $0.03 per diluted share verses Non-GAAP Earnings Per Share of $0.11) and Trulia Inc reported Q3 2014 earnings on October 29th (total revenue rose 67% to $67.1M along with an adjusted net loss of $2.8 million, or $0.08 per share on a basic and diluted basis, compared with adjusted net income of $9.1 million, or $0.26 and $0.24 per share on a basic and diluted basis, respectively). The acquisition of Move Inc and Trulia Inc though (assuming the Federal Trade Commission approves the deal)�really leaves Zillow Inc as the main publicly traded online real estate information.�

Top Warren Buffett Stocks To Watch For 2015: Alumina Ltd (AWCMF)

Alumina Limited (Alumina), is an Australia-based company. The Company is the holding company of WMC Group. Alumina is engaged in investing in bauxite mining, alumina refining and selected aluminum smelting operations, through its 40% ownership of Alcoa World Alumina and Chemicals (AWAC). The Company�� partner, Alcoa, owns the remaining 60% of AWAC, and is the manager. The Company�� subsidiaries include Alumina Finance Limited, Alumina Holdings (USA) Inc., Alumina International Holdings Pty. Ltd., Alumina Brazil Holdings Pty Ltd, Alumina Limited Do Brasil SA, Alumina (U.S.A.) Inc., Butia Participacoes SA, Westminer Acquisition (U.K.) Limited, Westminer International (U.K.) Limited and Westminer (Investments) B.V. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australia stocks tilted lower early Monday as the Sydney markets reacted to last week's disappointing jobs numbers out of the U.S., with the S&P/ASX 200 (AU:XJO) down 0.2% at 5,304.40. Data out Friday showed the U.S. added a net 74,000 jobs, trailing a forecast for 193,000 positions, and while Wall Street ended mixed following the numbers, Australian stocks will global exposure moved lower. Financial major Macquarie Group Ltd. (AU:MQG) (MCQEF) fell 1.8%, mall developer Westfield Group Australia (AU:WDC) (WEFIF) retreated 0.6%, and media firm News Corp. (AU:NWS) (NWS) -- the parent of MarketWatch, publisher of this report -- gave up 1.3%. But the jobs report also depressed the U.S. dollar, which helped boost prices for dollar-denominated commodities, and this in turn supported Australian resource shares. BHP Billiton Ltd. (AU:BHP) (BHP) gained 0.6%, Rio Tinto Ltd. (AU:RIO) (RIO) added 0.9%, Alumina Ltd. (AU:AWC) (AWCMF) rallied 4.5%, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) improved by 1.2%. A strong showing for Comex gold on Friday also sent Newcrest Mining Ltd.

• [By WWW.MARKETWATCH.COM]

  LOS ANGELES (MarketWatch) -- Australian stocks headed into a third day of gains Tuesday, as the S&P/ASX 200 (AU:XJO) rose 0.2% in early trade. Miners (except for gold miners) were among the leading advancers: Rio Tinto Ltd. (AU:RIO) (RIO) rose 0.9%, Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) gained 1.3%, Mt. Gibson Iron Ltd. (AU:MGX) tacked on 2.3%, Alumina Ltd. (AU:AWC) (AWCMF) traded 1.1% higher, and Whitehaven Coal Ltd. (AU:WHC) jumped 5.4% after posting a 26% increase in fiscal-2014 coal output and predicted a modest rebound for coking-coal prices later this year. A hike to the copper-production outlook at Oz Minerals Ltd. (AU:OZL) (OZMLF) was worth a 0.9% gain for the shares as well. On the other side of the ledger, the overnight sell-off in gold sent the volatile gold stocks dropping hard: Kingsgate Consolidated Ltd. (AU:KCN) (KSKGF) down 2.5%, Evolution Mining Ltd. (AU:EVN) (CAHPF) down 5.4%, St. Barbara Ltd. (AU:SBM) down 6.7%, and Sydney-listed shares of Alacer Gold Corp. (AU:AQG)

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australian stocks inched lower in early Friday trade, with the S&P/ASX 200 (AU:XJO) down 0.1% at 5,322.00, with weakness in miners outweighing mild strength in financials. Shares of BHP Billiton Ltd. (AU:BHP) (BHP) and Rio Tinto Ltd. (AU:RIO) (RIO) fell 1.4% apiece, while Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) lost 2.2% and gold miner Evolution Mining Ltd. (AU:EVN) (CAHPF) lost 0.8%, after copper prices fell to two-week lows and Chinese steel futures also lost ground, according to Reuters. The sector could react to Chinese trade data due out later in the day, as China remains a top market for Australian commodities. Stock in Alumina Ltd. (AU:AWC) (AWCMF) retreated 2.6% after its U.S. partner Alcoa Inc. (AA) posted a quarterly loss. On the upside, the big four banks all traded higher, with Commonwealth Bank of Australia (AU:CBA) (CBAUF) up 0.1%, National Australia Bank Ltd. (AU:NAB) (NAUBF) rising 0.2%, Westpac Banking Corp. (AU:WBC) (WEBN

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australian stocks nudged modestly higher early Thursday, with a rebound for financials offsetting weakness in the resource space. The S&P/ASX 200 (AU:XJO) advanced 0.1% to 5,361.80, as banks and brokers gained after losing ground late in the previous session on concerns about the health of major Chinese banks. Commonwealth Bank of Australia (AU:CBA) (CBAUF) and Macquarie Group Ltd. (AU:MQG) (MCQEF) rose 0.7% apiece, Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) added 0.5%, and Westpac Banking Corp. (AU:WBC) (WEBNF) improved by 0.5%. On the downside, losses for gold futures overnight sent Newcrest Mining Ltd. (AU:NCM) (NCMGF) down 1.3% and Evolution Mining Ltd. (AU:EVN) (CAHPF) 2.3% lower. The broader mining sector was also lower, with Alumina Ltd. (AU:AWC) (AWCMF) off 2.8%, BHP Billiton Ltd. (AU:BHP) (BHP) down 0.5%, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF)

5 Best Mid Cap Stocks To Buy Right Now: Adamis Pharmaceuticals Corp (ADMP)

Adamis Pharmaceuticals Corporation (Adamis), formerly Cellegy Pharmaceuticals, Inc., incorporated on April 22, 2004, operates through its wholly owned subsidiaries Cellegy Holdings, Inc., Adamis Corporation and Biosyn, Inc. Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc. (Adamis Viral) and Adamis Laboratories, Inc. (Adamis Labs). Adamis Labs is a specialty pharmaceutical company. The Company focuses on the development of preventive and therapeutic vaccine products and cancer drugs for patients with unmet medical needs. Adamis focuses on developing and commercializing products in the anti-inflammatory, allergy and respiratory field that are commercialized by the Company. Additional product candidates in its allergy and respiratory product pipeline include a steroid HFA (hydrofluoroalkane) metered dose inhaler product, referred to as APC-1000, for asthma and chronic obstructive pulmonary disease (COPD); a generic High-functioning autism (HFA) bronchodilator, referred to as APC-2000; and an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis, referred to as APC-3000.

Adamis Labs��product pipeline includes the single dose-epinephrine PFS syringe product and an inhaled nasal steroid product candidate, and additional asthma and allergy products. Adamis Labs is developing an aerosolized inhaled nasal steroid product, which it referred to as APC-3000, for the treatment of seasonal and perennial allergic rhinitis. The Company�� Adamis Viral subsidiary is focused on the development of Adamis��therapeutic vaccine product candidates and prostate cancer drugs for prostate cancer patients.

Drug Product Candidates in Development

APC-100 is an anti-inflammatory drug candidate. In animal studies, APC-100 demonstrated potent anti-androgenic and anti-inflammatory activities against prostate tumors growing in animal models and showed a safety profile in preclinical safety studies. APC-100! has demonstrated pharmacological characteristics as an oral or injectable anti-inflammatory and anti-androgenic drug candidate with multiple mechanisms of action. APC-100 decreases secretion of human Prostate Specific Antigen (PSA), by human prostate cancer cells growing in mice and also increases the time-to-tumor progression and survival of PCa mice with CS-PCa and CR-PCa tumors.

APC-200 is a drug candidate for both castrate-sensitive and castrate resistant prostate cancer. APC-200 blocks androgen-induced hydrogen peroxide production and inflammation and inhibits mouse PCa. In animal studies, APC-200 was an inhibitor of chronic inflammation, also completely inhibiting oxidase mediated high rates of hydrogen peroxide. APC-200 is developed as an oral drug, specifically in appropriate formulations for patients with PCa.

APC-300 is a multi-targeted small molecule therapeutic drug, which demonstrates anti-inflammatory, pro-apoptotic anti-cancer activities for prostate cancer patients, including men with metastatic CR-PCa. In pre-clinical in vivo studies conducted, APC-300 demonstrated the ability to inhibit human tumor growth and kill both castrate-sensitive and castrate-resistant human prostate cancer tumors. It also decreased human tumor volumes and suppressed local metastasis in human xenograft models, where malignant human prostate or human melanoma tumor tissue was grafted onto athymic immunosuppressed experimental mice. APC-300 inhibited human androgen receptor protein production in these studies. It also inhibited PSA secretion by human PCa cells, which is a serum marker for human prostate cancer.

The Company competes with Medivation, TEVA Pharmaceutical Industries Ltd and AstraZeneca.

Advisors' Opinion:

• [By Bryan Murphy]

  Although the market seems to be losing traction, and even losing ground now, the same can't be said of every single stock. A handful of stocks like China Jo-Jo Drugstores Inc. (NASDAQ:CJJD), Vuzix Corp. (OTCBB:VUZI), and Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) are forging ahead, doling out gains against the grain. Not that moving higher while other names are moving lower is a sure sign that ADMP, VUZI, and CJJD will remain in their uptrends indefinitely, but it sure doesn't hurt their odds. Here's a closer look at each one and why you'd want to add them to your watchlist.

5 Best Mid Cap Stocks To Buy Right Now: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Advisors' Opinion:

• [By Sean Williams]

  The waiting game
  The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma's (NASDAQ: GALE  ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off.

5 Best Mid Cap Stocks To Buy Right Now: DST Systems Inc. (DST)

DST Systems, Inc. provides information processing and software services and products. The company operates in two segments, Financial Services and Customer Communications. The Financial Services segment offers various solutions primarily to the asset management, brokerage, retirement, insurance, and healthcare industries. It provides proprietary software systems, including shareowner recordkeeping and distribution support systems for the United States and international mutual fund companies, broker/dealers, and financial advisors; and a defined-contribution participant recordkeeping system for the United States retirement plan market. This segment also offers investment management systems for the United States and international investment managers and fund accountants; a business process management and customer contact system for various industries; and medical and pharmacy claims administration processing systems and services for providers of healthcare plans, third party administrators, medical practice groups, and pharmacy benefit managers. The Customer Communications Segment helps businesses deploy customer communications while improving operational performance across critical business functions, such as sales, marketing, customer service, technology, finance, operations, and compliance. This segment helps clients deliver information in the desired combination of print, digital, and archival formats. Its product offering combines data insights and analysis with business decision-making tools, and multi-channel execution and delivery designed to help businesses acquire, grow, retain, and win back customers. The company also owns and operates real estate properties, as well as has investments in equity securities, private equity funds, and other financial interests. It has operations in the United States, the United Kingdom, Canada, Australia, and internationally. DST Systems, Inc. was founded in 1968 and is based in Kansas City, Missouri.< /p> Advisors' Opinion:

• [By Vera Yuan]

  ��nformation processing company DST Systems, Inc. (DST) declined as the company conducted a secondary offering of common stock for a selling shareholder, Argyros Group.

• [By Rich Duprey]

  Data center operator DST Systems (NYSE: DST  ) will pay a second-quarter dividend of $0.30 per share, the same rate it paid last quarter after switching from a semiannual payout schedule to a quarterly one, the company announced yesterday.